The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Mortality in Overweight and Underweight Children With Acute Myeloid Leukemia
Abstract
CONTEXT: Current treatment for acute myeloid leukemia (AML) in children cures about half the patients. Of the other half, most succumb to leukemia, but 5% to 15% die of treatment-related complications. Overweight children with AML seem to experience excess life-threatening and fatal toxicity. Nothing is known about how weight affects outcomes in pediatric AML. OBJECTIVE: To compare survival rates in children with AML who at diagnosis are underweight (body mass index [BMI] < or =10th percentile), overweight (BMI > or =95th percentile), or middleweight (BMI = 11th-94th percentiles). DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of BMI and survival in 768 children and young adults aged 1 to 20 years enrolled in Children's Cancer Group-2961, an international cooperative group phase 3 trial for previously untreated AML conducted August 30, 1996, through December 4, 2002. Data were collected through January 9, 2004, with a median follow-up of 31 months (range, 0-78 months). MAIN OUTCOME MEASURES: Hazard ratios (HRs) for survival and treatment-related mortality. RESULTS: Eighty-four of 768 patients (10.9%) were underweight and 114 (14.8%) were overweight. After adjustment for potentially confounding variables of age, race, leukocyte count, cytogenetics, and bone marrow transplantation, compared with middleweight patients, underweight patients were less likely to survive (HR, 1.85; 95% confidence interval [CI], 1.19-2.87; P = .006) and more likely to experience treatment-related mortality (HR, 2.66; 95% CI, 1.38-5.11; P = .003). Similarly, overweight patients were less likely to survive (HR, 1.88; 95% CI, 1.25-2.83; P = .002) and more likely to have treatment-related mortality (HR, 3.49; 95% CI, 1.99-6.10; P<.001) than middleweight patients. Infections incurred during the first 2 courses of chemotherapy caused most treatment-related deaths. CONCLUSION: Treatment-related complications significantly reduce survival in overweight and underweight children with AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
BODEY, G. P., BUCKLEY, M., SATHE, Y. S., & FREIREICH, E. J. (1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-2-328 · Cited by 2,469
Ogden, C. L., Kuczmarski, R. J., Flegal, K. M., Mei, Z., Guo, S., Wei, R., Grummer-Strawn, L. M., Curtin, L. R., Roche, A. F., & Johnson, C. L. (2002) · Pediatrics · doi:10.1542/peds.109.1.45 · Cited by 2,018
BENNETT, J. M., CATOVSKY, D., DANIEL, M.-T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-3-460 · Cited by 737
Wheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M., Harrison, C. J., Rees, J. K. H., Stevens, R. F., & Walker, H. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01684.x · Cited by 434
Talcott, J. A. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.148.12.2561 · Cited by 363
Raimondi, S. C., Chang, M. N., Ravindranath, Y., Behm, F. G., Gresik, M. V., Steuber, C. P., Weinstein, H. J., & Carroll, A. J. (1999) · PubMed · doi:10.1182/blood.v94.11.3707 · Cited by 323
Meyerhardt, J. A., Catalano, P. J., Haller, D. G., Mayer, R. J., Benson, A. B., Macdonald, J. S., & Fuchs, C. S. (2003) · Cancer · doi:10.1002/cncr.11544 · Cited by 306
Doxorubicin clearance in the obese.
Rodvold, K. A., Rushing, D. A., & Tewksbury, D. A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.8.1321 · Cited by 213
Rosner, G. L., Hargis, J. B., Hollis, D. R., Budman, D. R., Weiss, R. B., Henderson, I. C., & Schilsky, R. L. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.3000 · Cited by 178
Bastarrachea, J., Hortobagyi, G. N., Smith, T. L., Kau, S.-W. C., & Buzdar, A. U. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-1-199401010-00004 · Cited by 171
Riley, L., Hann, I. M., Wheatley, K., & Stevens, R. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01550.x · Cited by 126
Sekeres, M. A. (2004) · Blood · doi:10.1182/blood-2003-09-3118 · Cited by 114
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients
Powis, G., Reece, P. A., Ahmann, D. L., & Ingle, J. N. (1987) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00570489 · Cited by 112
Influence of obesity on drug disposition.
Blouin, R. A., Kolpek, J. H., & Mann, H. J. (1987) · PubMed · Cited by 108
Obesity and autologous stem cell transplantation in acute myeloid leukemia
Meloni, G., Proia, A. S., Capria, S., Romano, A., Trapè, G., Trisolini, S. M., Vignetti, M., & Mandelli, F. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703145 · Cited by 70
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution
Lind, M., Margison, J. M., Cerny, T., Thatcher, N., & Wilkinson, P. M. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00692355 · Cited by 66
Poikonen, C. B. P. (2001) · Acta Oncologica · doi:10.1080/028418601750071082 · Cited by 65
The Effect of Obesity on Neutrophil Fc Receptors and Adhesion Molecules (CD16, CD11b, CD62L)
Cottam, D. R., Schaefer, P. A., Fahmy, D. E., Shaftan, G. W., & Angus, L. D. G. (2002) · Obesity Surgery · doi:10.1381/096089202762552674 · Cited by 49
Dysfunctional Immune-Privilege In Morbid Obesity: Implications and Effect of Gastric Bypass Surgery
Cottam, D. R., Schaefer, P. A., Shaftan, G. W., & Angus, L. D. G. (2003) · Obesity Surgery · doi:10.1381/096089203321136584 · Cited by 37
Cited by
Falagas, M. E., & Kompoti, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70523-0 · Cited by 811
The distinctive biology of cancer in adolescents and young adults
on behalf of the Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology, Bleyer, A., Barr, R., Hayes-Lattin, B., Thomas, D., Ellis, C., & Anderson, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2349 · Cited by 660
American Society of Clinical Oncology Position Statement on Obesity and Cancer
Ligibel, J. A., Alfano, C. M., Courneya, K. S., Demark-Wahnefried, W., Burger, R. A., Chlebowski, R. T., Fabian, C. J., Gucalp, A., Hershman, D. L., Hudson, M. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.4680 · Cited by 526
Clinical implications of FLT3 mutations in pediatric AML
Meshinchi, S., Alonzo, T. A., Stirewalt, D. L., Zwaan, M., Zimmerman, M., Reinhardt, D., Kaspers, G. J. L., Heerema, N. A., Gerbing, R., Lange, B. J., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009233 · Cited by 395
Self-citationLange, B. J., Smith, F. O., Feusner, J., Barnard, D. R., Dinndorf, P., Feig, S., Heerema, N. A., Arndt, C., Arceci, R. J., Seibel, N., et al. (2008) · Blood · doi:10.1182/blood-2007-04-084293 · Cited by 274
Self-citation
Metadata
- Authors
- Lange, B. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-01-12
- Volume
- 293
- Issue
- 2
- Pages
- 203
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1992371348
- Cited by
- 295
- References
- 22
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.